Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2

Alnylam Pharmaceuticals (NASDAQ:ALNY) was the best performing large cap ($30B+) pharma or biotech in Q2, returning ~58.5% in the period.

The biotech’s strong performance was helped significantly in late June when it reported strong pivotal trial results for vutrisiran, a treatment for ATTR amyloidosis with cardiomyopathy, sending shares skyrocketing.